Pharmaceutical company Taiwan Liposome Company Ltd (Nasdaq:TLC)(TWO:4152) revealed on Monday the launch of an exclusive partnership in China to commercialise two liposomal products utilising its proprietary NanoX technology platform in the therapeutic areas of oncology and severe infectious diseases with 3SBio Inc (HKEX:1530).

The partnership allows TLC and 3SBio to obtain regulatory approvals in mainland China; TLC will utilise its commercial-scale manufacturing capabilities to supply the two liposomal products for 3SBio to commercialise in mainland China.

Additionally, the partnership will focus in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology and oncology.

Pursuant to the agreement, TLC is eligible to receive up to USD25m in upfront payments for each product and subsequent regulatory and sales milestone payments as well as is eligible a share of the potential profits from product sales. Additional financial terms were not disclosed.

In conjunction, TLC's NanoX active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site.